Defining PSSD
Post-SSRI Sexual Dysfunction (PSSD) is defined by the persistence of sexual dysfunction and/or emotional blunting after the discontinuation of SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-norepinephrine reuptake inhibitor) antidepressants. The key diagnostic criterion is that symptoms arise during treatment and continue after the drug has been stopped — often for months, years, or indefinitely.
The condition was formally recognised by the European Medicines Agency (EMA) in 2019 following a safety review. The EMA concluded that the evidence supported a causal relationship between SSRI/SNRI use and persistent sexual dysfunction, and mandated that all product information for these medications include PSSD as a potential adverse effect. This was a watershed moment: for the first time, a major regulatory body had officially acknowledged what patients had been reporting for decades.
History of PSSD Recognition
Reports of persistent sexual dysfunction after SSRI discontinuation began appearing in the medical literature in the 1990s, shortly after SSRIs became widely prescribed. However, these reports were largely dismissed by the medical establishment and pharmaceutical companies for over two decades.
The turning point came with a landmark 2019 paper by Healy et al., which documented 62 patients across 23 countries experiencing persistent sexual and emotional symptoms after stopping SSRIs. The majority of these patients reported that their physicians had dismissed or minimised their symptoms. This paper, combined with growing patient advocacy and the accumulation of case reports in the literature, prompted the EMA review that led to formal recognition.
Which Antidepressants Are Implicated?
PSSD has been reported with all major SSRIs and SNRIs. The following table summarises the medications most commonly implicated in published case reports and patient surveys:
| Medication | Class | PSSD Cases Reported | Notes |
|---|---|---|---|
| Sertraline (Zoloft) | SSRI | Most commonly reported | Most widely prescribed SSRI globally |
| Paroxetine (Paxil) | SSRI | Frequently reported | Highest discontinuation syndrome risk |
| Fluoxetine (Prozac) | SSRI | Frequently reported | Long half-life |
| Escitalopram (Lexapro) | SSRI | Commonly reported | — |
| Venlafaxine (Effexor) | SNRI | Reported | Also causes discontinuation syndrome |
| Duloxetine (Cymbalta) | SNRI | Reported | — |
How PSSD Differs From Temporary SSRI Sexual Side Effects
The distinction between temporary SSRI sexual side effects and PSSD is critical for diagnosis and patient advocacy:
- Temporary SSRI sexual side effects occur during treatment and resolve within days to weeks of stopping the medication. They are dose-dependent and affect the majority of SSRI users to some degree.
- PSSD is defined by persistence after discontinuation. Symptoms may begin during treatment but continue — and in some cases worsen — after the drug is stopped. There is no dose-response relationship in the same way; PSSD has been reported after very short courses and low doses.
Who Is at Risk?
PSSD can affect anyone who takes an SSRI or SNRI. Risk factors that have been proposed in the literature include longer duration of treatment, higher doses, younger age at first exposure, and possibly genetic variants in serotonin receptor genes — but none of these have been confirmed as reliable predictors. Cases have been documented after a single dose in rare instances.
The condition affects men and women roughly equally in terms of symptom burden, though the specific manifestations differ. Men more commonly report erectile dysfunction and ejaculatory dysfunction; women more commonly report vaginal numbness and anorgasmia. Emotional blunting is reported at similar rates across sexes.
Explore Shrooomz Botanical Supplements
USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.
View Our Supplements →Return to the PSSD Resource Hub for the complete cluster of articles. Related: Can Psilocybin Help With PSSD? | Emotional Numbness After Stopping Antidepressants | SSRI Genital Numbness | Psilocybin vs Antidepressants
Ready to experience the difference?
Shop Secret Shrooomz →Frequently Asked Questions
What is PSSD?
PSSD stands for Post-SSRI Sexual Dysfunction. It refers to persistent sexual dysfunction that begins during SSRI/SNRI treatment and continues after stopping the medication. The evidence base consists mainly of case reports and small studies, and regulatory bodies like the EMA have acknowledged the condition.
How long does PSSD last?
Durations reported in the literature vary widely. Some individuals report symptoms for months or years after stopping the drug, and a minority describe persistence for an indefinite period. Much of the data come from case reports and small series, so precise prevalence and typical duration remain uncertain.
What symptoms are involved?
Symptoms commonly affect sexual desire, arousal, and orgasm, including decreased libido, erectile or lubrication difficulties, delayed or absent orgasm, and genital numbness. Some people also report emotional blunting or reduced emotional responsiveness. Symptoms can present differently across individuals.
How is PSSD diagnosed?
Diagnosis is clinical, based on a history of onset during SSRI/SNRI use with persistence after discontinuation, and after other medical causes have been ruled out. There is no specific lab test or imaging that confirms PSSD. Clinicians typically take a careful medication and symptom history and may suggest gradual taper if still on antidepressants.
Can PSSD be treated or reversed?
There is no proven, standardized treatment for PSSD. Some clinicians pursue symptomatic approaches (e.g., PDE-5 inhibitors for erectile dysfunction) or psychotherapy, but robust evidence from randomized trials is lacking. Some individuals report improvement over time, but outcomes are highly variable.
What should I do if I think I have PSSD?
If you suspect PSSD, document your symptom history and discuss it with your clinician or psychiatrist, ideally after discontinuing the SSRI/SNRI if feasible. Seek a medical evaluation to exclude other causes (hormonal issues, chronic illness, substance use). While waiting for guidance, avoid self-medication and consider supportive therapies and peer support.